Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer.
about
Cancer cell death enhances the penetration and efficacy of oncolytic herpes simplex virus in tumorsEvaluation of adenovirus capsid labeling versus transgene expressionBiological approaches to therapy of pancreatic cancer.Reduction of nontarget infection and systemic toxicity by targeted delivery of conditionally replicating viruses transported in mesenchymal stem cellsReplication-selective virotherapy for cancer: Biological principles, risk management and future directions.Adenovirus E1A: remodelling the host cell, a life or death experience.Developing novel oncolytic adenoviruses through bioselectionE1A sensitizes cells to tumor necrosis factor alpha by downregulating c-FLIP S.Inhibition of the inflammatory cytokine TNF-α increases adenovirus activity in ovarian cancer via modulation of cIAP1/2 expression.Active targeting of RGD-conjugated bioreducible polymer for delivery of oncolytic adenovirus expressing shRNA against IL-8 mRNA.Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes.The oncolytic virotherapy treatment platform for cancer: unique biological and biosafety points to consider.A systematic comparison of the anti-tumoural activity and toxicity of the three Adv-TKspH-sensitive oncolytic adenovirus hybrid targeting acidic tumor microenvironment and angiogenesisCytotoxic effects of replication-competent adenoviruses on human esophageal carcinoma are enhanced by forced p53 expression.Gene therapy in gynecological cancer.A vesicular stomatitis virus glycoprotein epitope-incorporated oncolytic adenovirus overcomes CAR-dependency and shows markedly enhanced cancer cell killing and suppression of tumor growth.Myxoma virus and oncolytic virotherapy: a new biologic weapon in the war against cancer.Therapeutic efficacy of an oncolytic adenovirus containing RGD ligand in minor capsid protein IX and Fiber, Δ24DoubleRGD, in an ovarian cancer modelVaccinia virus, a promising new therapeutic agent for pancreatic cancer.CEACAM6 attenuates adenovirus infection by antagonizing viral trafficking in cancer cells.Redirecting adenovirus tropism by genetic, chemical, and mechanical modification of the adenovirus surface for cancer gene therapy.Evolving lessons on nanomaterial-coated viral vectors for local and systemic gene therapy.Glial fibrillary acidic protein promoters direct adenovirus early 1A gene and human telomerase reverse transcriptase promoters direct sodium iodide symporter expression for malignant glioma radioiodine therapy.RNA interference-mediated knockdown of p21(WAF1) enhances anti-tumor cell activity of oncolytic adenoviruses.Oncolytic Viral Therapy for Mesothelioma.Conditionally replicating adenoviruses kill tumor cells via a basic apoptotic machinery-independent mechanism that resembles necrosis-like programmed cell death.Effect of hypoxia on Ad5 infection, transgene expression and replication.Productive replication of human adenovirus type 5 in canine cells.Tumor-specific gene therapy for uterine cervical cancer using MN/CA9-directed replication-competent adenovirus.Selective disruption of an oncogenic mutant allele by CRISPR/Cas9 induces efficient tumor regressionAdenovirus-mediated decorin expression induces cancer cell death through activation of p53 and mitochondrial apoptosis.The effect of hypoxia on the uptake, replication and lytic potential of group B adenovirus type 3 (Ad3) and type 11p (Ad11p).Use of synthetic vectors for neutralising antibody resistant delivery of replicating adenovirus DNA.Conditionally replicating viruses in cancer therapy.Telomerase-dependent oncolytic adenovirus for cancer treatment.ADP-overexpressing adenovirus elicits enhanced cytopathic effect by induction of apoptosis.Hypoxia reduces adenoviral replication in cancer cells by downregulation of viral protein expression.Evaluation of E1B gene-attenuated replicating adenoviruses for cancer gene therapy.Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma.
P2860
Q24614856-9CDA2C61-2CC4-45A9-BEC8-AABA202DF40FQ33669272-E89E6B19-4795-4CEC-8896-4B49002CC8E3Q33899938-9C36AB61-1DD0-4D3F-9BD8-E4E34550B8EBQ34154904-293E0D66-D4C3-4986-A7F6-FE3B910FDF29Q34297058-8ACBA9E9-B176-4F0A-9031-BE2FB9C34B48Q34468761-FB9A07B1-8532-4BE1-9E2D-FEA598505069Q34471952-FDE451B1-1B34-43DA-B9E0-CEC3346A49F1Q34472155-1C0CC119-8AD6-466A-AF05-8DB7458C5B07Q34621683-65BDBCAB-E49B-474C-88D3-7B8BAFCC5796Q35000513-8E631F8C-90BF-4035-AC3D-256811B79D81Q35043106-AF91F90D-6A5E-451E-A07B-F7F6CA27F1D4Q35043121-ECA4DB6D-E048-4F6F-83FA-DBFDE96196F9Q35145614-F40FBD31-A236-455F-B49A-1DBCB1543C3FQ35569909-1E7F9439-0CF2-4D4B-A2B6-7E41E19B606EQ35659029-6EC11094-9F9C-4D4E-9E8C-70AA1E649CFCQ36532089-7510A65C-CAF0-4453-A509-6E999DA8BEB8Q36544244-6E682543-03DD-4F61-A36E-3ED2CCDE07FFQ36922264-6BCE546D-D05A-40DE-AC69-8524C7671D64Q37127836-5D86FAC9-F131-49A8-B345-4C4C9AF13963Q37158473-D31273BB-5BE9-40F9-959D-D75F8AD7485AQ37209263-EA42C7B0-5A77-44D1-8191-F121D02D06EAQ38769919-8A0F1FD3-B649-435D-BC3D-1AFFDD18EB2CQ38848060-25AAF4C0-FAAB-4BAF-ACD5-0CD65ABFCA5DQ38939127-EBE5FEA4-60A0-4320-B468-E5FF43648161Q39858149-DBA8207F-603D-48E6-B478-E7AD70DA76C8Q40051845-8D400818-CC0B-4B32-9491-8318EC32B37CQ40277603-C4302810-1C9A-4702-920E-91C98F0E3740Q40462233-F4A33A8B-0498-4711-8D0F-DE9B3EC6EB78Q40478143-131D557B-3152-4DC0-BA2D-AB095CBE4C6EQ40551014-11BCDFA0-CEBC-43F0-9BAD-A8197B3EFD50Q41511092-6BBA1085-5E25-4A64-8AE7-1F0F117433E8Q44446478-2B1C0962-932E-4AB2-A085-4676C310D2A8Q45856648-6C7FE5C5-C645-4901-B092-E329C3D87872Q45859390-D0B462E4-7FB7-4B3D-9AB5-2BAE3B9703A2Q45861487-0380F96B-19EC-47F0-9B85-74658AC4C2EFQ45863661-77DCB756-0929-4376-A59A-70C1A9392152Q45877985-BFCCC358-B716-44C3-B0C0-E4609F4EBE8EQ45881054-E29F764B-B4FD-4C0B-A05B-0040CB175F1EQ45888713-14D96651-DEC1-4AA0-B997-35BCF8B8BEEBQ50047493-19E1992B-EA2B-430B-9A46-3E38890C9932
P2860
Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer.
description
2000 nî lūn-bûn
@nan
2000 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Replication-selective oncolyti ...... at genetic targets in cancer.
@ast
Replication-selective oncolyti ...... at genetic targets in cancer.
@en
Replication-selective oncolyti ...... at genetic targets in cancer.
@nl
type
label
Replication-selective oncolyti ...... at genetic targets in cancer.
@ast
Replication-selective oncolyti ...... at genetic targets in cancer.
@en
Replication-selective oncolyti ...... at genetic targets in cancer.
@nl
prefLabel
Replication-selective oncolyti ...... at genetic targets in cancer.
@ast
Replication-selective oncolyti ...... at genetic targets in cancer.
@en
Replication-selective oncolyti ...... at genetic targets in cancer.
@nl
P2860
P356
P1433
P1476
Replication-selective oncolyti ...... at genetic targets in cancer.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.ONC.1204094
P407
P577
2000-12-01T00:00:00Z
P6179
1027120309